Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections - PubMed
4 days ago
- #ceftriaxone resistance
- #E. coli ST131
- #carbapenem use
- Escherichia coli ST131, particularly its subclade C2/H30Rx, is a major contributor to ceftriaxone-resistant E. coli bloodstream infections (BSI).
- A study involving 282 patients showed that 43% of E. coli BSI cases were ST131, with 23% belonging to the C2/H30Rx subclade.
- Resistance to ceftriaxone was significantly higher in ST131 (79%) and C2/H30Rx (86%) compared to non-ST131 E. coli (27%).
- Patients with ST131 BSI were older and more frequently admitted from long-term care facilities compared to non-ST131 cases.
- Carbapenem use was more common in treating ST131 BSI (74% overall, 48% empiric) than non-ST131 BSI (31% overall, 19% empiric).
- Desirability of outcome ranking (DOOR) at 30 days was similar between ST131 and non-ST131 BSI groups.